Sofinnova Crossover I — Form SCHEDULE 13D/A
Filed July 6, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Sofinnova Crossover I, a Paris-based investor (CIK 0001845105), filed an amended Schedule 13D/A on July 6, 2026, regarding beneficial ownership in Abivax S.A., a French pharmaceutical company (SIC 2834, CIK 0001956827). The filing itself does not disclose the specific shareholding percentages, dollar amounts, or details of what changed from the original Schedule 13D; only that an amendment was made.
Why this rating
Standard Schedule 13D amendment filing; no material operational change disclosed. Company scale unknown; amendment nature routine unless underlying stake is transformational.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.